What Researchers Did
Researchers conducted a randomized trial to evaluate the safety and effectiveness of adding misonidazole, a hypoxic cell sensitizer, to high-dose radiation therapy for patients with advanced, unresectable squamous cell carcinoma of the head and neck.
What They Found
Out of 40 patients analyzed, 21 received radiation plus misonidazole. Misonidazole was associated with minor side effects in a few patients, such as persistent numbness (1 patient) and nausea (2 patients). The initial complete response rates were 53% for radiation alone and 48% for radiation plus misonidazole, while 2-year loco-regional control rates were 10% and 17% respectively, showing no significant improvement with misonidazole.
What This Means for Canadian Patients
This study suggests that adding misonidazole to high fractional dose radiotherapy does not significantly improve outcomes for patients with advanced, unresectable head and neck cancers. Canadian patients with similar conditions would therefore likely not be offered this specific drug combination as an effective treatment strategy.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study's findings are limited by its relatively small sample size of 40 patients and its age, having been conducted between 1979 and 1983.